fbpx
7-12-2021

DeepIntent Awarded Patent for DeepIntent Outcomes™ Technology, Which Optimizes Advertising Campaigns to Increase Script Lift Using Real-World Clinical Data

With patented technology, the DeepIntent® Demand Side Platform is the first and only proven Demand Side Platform to drive up to 35%* higher script lift through the use of real-world clinical data

NEW YORK, July 12, 2021 – DeepIntent, the leading independent healthcare marketing technology company built purposefully to influence patient health and business outcomes, announced it has been awarded a patent for DeepIntent Outcomes from the United States Patent and Trademark Office. This makes DeepIntent the only demand side platform (DSP) using patented technology to link real-world clinical data with impression data to measure and optimize live campaigns toward audience quality (AQ) and script performance metrics.

With DeepIntent’s patented technology, healthcare marketers can measure and algorithmically optimize live campaigns toward real-world business outcomes, such as AQ and script lift (TRx, NRx, NBRx), based on prescribing behaviors and verified exposures against the industry’s most timely and comprehensive clinical and pharmaceutical datasets.

“DeepIntent Outcomes represents the culmination of five years in healthcare marketing innovation to unify campaign planning, activation, measurement, and optimization,” said DeepIntent CEO Chris Paquette. “Aided by the industry’s most comprehensive, timely, and actionable datasets, DeepIntent Outcomes enables marketers to go beyond clicks and impressions to zero in on the metrics that matter. Daily data refreshes give marketers the confidence to know their campaigns are optimized toward real-world business performance, yielding better patient outcomes.”

DeepIntent Outcomes, launched earlier this year, brings significant, differentiated features and capabilities to the market. Those include measuring how key campaign parameters, such as audience, media, and messaging, drive script lift. Each aspect of campaign performance is considered and auto-optimized by privacy-safe machine learning algorithms that select the optimal creative, audience, frequency, context, and locations to serve ads. The optimization algorithms also help uncover unexpected insights in real-time, resulting in lowered costs and unprecedented ROI.

“DeepIntent is a visionary company that shares our mission to ensure patients are receiving the right treatment at the right time. Leveraging Komodo Health’s comprehensive real-world database within its platform and DeepIntent’s DSP, marketers can chart the connections between advertising campaigns and patient outcomes,” said Lauren Stahl, Vice President and Head of Partnerships, Healthcare Solutions at Komodo Health, a healthcare software company that has built the industry’s largest and most complete database of de-identified, real-world patient data. “In our partnership with DeepIntent, healthcare marketers can manage their campaigns with unprecedented speed and precision, and ultimately, improve outcomes.”

DeepIntent Outcomes uniquely allows healthcare marketers to:

  • Plan and coordinate healthcare provider and direct-to-consumer campaigns based on patient and provider insights, including past and present script performance;
  • Activate media across channels, including display, video, and connected TV, and devices while bidding to improve business outcomes;
  • Measure how each campaign is performing in real-time; and
  • Optimize in-flight campaigns by automatically adjusting campaign parameters to increase audience quality and scripts while maximizing media efficiency.

To learn more about DeepIntent Outcomes, or to schedule a live demo of the DSP, visit www.deepintent.com/deepintent-outcomes.

*as proven in beta

About DeepIntent
Conceived by former Memorial Sloan Kettering data scientists, DeepIntent connects healthcare companies with patients and providers across every device through unique data, media partnerships, and integrations. From campaign planning to audience targeting to measuring and optimization, DeepIntent is proven to increase script lift while improving patients’ quality of life. Its Healthcare Marketing Platform empowers marketers at seven of the top ten pharmaceutical companies and leading healthcare advertising agencies to positively influence health and business outcomes. For more information, visit DeepIntent.com or find us on Twitter, Facebook, or LinkedIn.

Press Contact
Finn Partners for DeepIntent
Mena Buscetto
deepintent@finnpartners.com
860-326-1698

More Insights

DeepIntent Selected as Exclusive Healthcare DSP for LG Ads Solutions in the U.S.
11-10-2021

Effective immediately, DeepIntent will have exclusive rights as the only DSP healthcare advertisers can use to reach LG Ads Solutions’ 20+ million households nationwide NEW…

Read More
DeepIntent Survey Reveals That Pharmaceutical Advertising Motivates Patients to Research Treatment and Medication Options
10-27-2021

NEW YORK, Oct. 27, 2021 — DeepIntent, the leading independent healthcare marketing technology company built purposefully to influence patient health and business outcomes, today released…

Read More
DeepIntent Named a Company of the Year in PM360 2021 Trailblazer Awards
10-11-2021

NEW YORK, Oct. 11, 2021 — PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has…

Read More
Subscribe to Our NewsletterJoin our mailing list to get the latest product updates, actionable insights, and resources for healthcare marketers and publishers.

By clicking ‘Submit’ you agree to our Terms and Privacy Policy